What is L-Pyroglutamic Acid Powder?

L-Pyroglutamic Acid (L-PGA) is a chiral non-protein amino acid derived from glutamic acid, appearing as a white crystalline powder (molecular formula: C₅H₇NO₃). It acts as a key intermediate in peptide synthesis and exhibits bioactive properties, including neuroprotection, antioxidant effects, and moisture retention. XJESON’s synthetic L-PGA powder eliminates risks associated with natural extraction (e.g., inconsistent purity from plant sources like Gastrodia elata 2) and delivers ≥99.5% HPLC-verified purity, complying with USP/EP standards for global pharmaceutical and nutraceutical use.

Key Benefits & Applications

 1. Pharmaceutical raw materials

• Neuroprotective Drug Synthesis:
• Serves as a critical building block for SGLT-2 inhibitors (e.g., Rongliflozin cocrystals in diabetes therapy 6) and anti-epileptic agents.
• Mechanism: Modulates GABAergic pathways to reduce neuronal excitability.
• Antibiotic & Anti-Inflammatory Agents:
• Intermediate for antibiotics (e.g., ceftibuten) and NSAIDs. Dosage forms: Tablets, injectables (endotoxin <0.1 EU/mg).

2. Health care material Formulations

• Cognitive Health Supplements:
• Enhances memory and neuroprotection at 250–500 mg/day doses. Combined with bacopa monnieri for synergistic effects.
• Clinical relevance: Reduces oxidative stress in hippocampal neurons (search growth: 120% for "cognitive health" keywords).

3. Cosmetics materials

• Anti-Aging & Moisturizing Agent:
• Boosts hyaluronic acid synthesis and keratinocyte hydration. Used in serums (0.5–2% concentration) and creams.
• Market trend: Aligns with "Clean Beauty" demand (30% CAGR in natural cosmetics 1).

4. Agricultural Bio-Stimulants

• Plant Growth Enhancer:
• Upregulates nitrogen metabolism genes (e.g., Os01g0322700 by 119x) and increases chlorophyll synthesis (3.2x higher in rice trials 7).

Technical Specifications (XJESON L-PGA Powder)

Market-Driven Applications & Case Studies

XJESON Quality Assurance

• Traceability: Batch-specific COA with HPLC, MS, NMR, and residual solvent reports.
• Stability: 36-month shelf life at -20°C; potency retention >98.5%.
• Customization:
• Particle size: 50–200 μm (direct compression) or <50 μm (enhanced bioavailability).
• Purity: 98%, 99%, 99.5%, or custom grades.

FAQs for B2B Clients

Q1: Can L-PGA powder be used in injectable drugs?

A: Yes. XJESON offers endotoxin-controlled (<0.1 EU/mg) L-PGA suitable for parenteral formulations. Full DMF support included.

Q2: Why choose synthetic over natural L-PGA?

A: Synthetic L-PGA ensures batch consistency, eliminates plant-derived contaminants (e.g., pesticides in Gastrodia elata 2), and reduces costs by 25%.

Q3: Is L-PGA effective in NAFLD nutraceuticals?

A: Yes. At 300 mg/day, it reduces hepatic oxidative stress and synergizes with silymarin.

Q4: How to handle bulk L-PGA for stability?

A: Store below -20°C in vacuum-sealed bags. Avoid moisture/light exposure. XJESON provides validated storage protocols.